NYSE · HCA
HCA Healthcare, Inc.
$478.08+$14.86 (+3.21%)
HCA Healthcare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.09% below the high.
Loading market information…
XETRA · FME.DE · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:36 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Fresenius Medical Care AG & Co. KGaA’s quoted price sits in the upper half of its reported 52-week range, 12.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Fresenius Medical Care AG & Co. KGaA’s forward annual dividend is €1.49 per share, paid annual. The forward yield is 3.59% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Fresenius Medical Care AG & Co. KGaA’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of €1.16. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fresenius Medical Care AG & Co. KGaA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 6, 2025 | €0.81+11.74% vs estimate | €4.88B+7.46% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | €0.91+13.25% vs estimate | €5.08B+7.46% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | €0.82+26.15% vs estimate | €4.76B-7.54% vs estimate |
|---|
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$478.08+$14.86 (+3.21%)
HCA Healthcare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.09% below the high.
€47.00+€0.67 (+1.44%)
Fresenius SE & Co. KGaA’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$270.57+$2.07 (+0.77%)
Tenet Healthcare Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.41% below the high.
R$32.35-R$1.34 (-3.98%)
Rede D'Or São Luiz S.A.’s quoted price sits in the lower half of its reported 52-week range, 33.17% below the high.
$131.49+$9.41 (+7.7%)
Encompass Health Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.69% below the high.
₹8,200.00+₹63.00 (+0.77%)
Apollo Hospitals Enterprise Limited’s quoted price sits in the upper half of its reported 52-week range, 9.6% below the high.
$193.31+$9.38 (+5.1%)
DaVita Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.89% below the high.
$23.50-$1.96 (-7.7%)
Baxter International Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.67% below the high.
